Trial Profile
A Phase Ib/II Study of MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 06 Dec 2023
Price :
$35
*
At a glance
- Drugs Binimetinib (Primary) ; Imatinib
- Indications Gastrointestinal stromal tumours
- Focus Adverse reactions; Therapeutic Use
- 01 Dec 2023 Planned End Date changed from 1 Nov 2023 to 1 Nov 2024.
- 01 Dec 2023 Planned primary completion date changed from 1 Nov 2023 to 1 Nov 2024.
- 28 Dec 2022 Planned End Date changed from 1 Nov 2022 to 1 Nov 2023.